Gene Expression Profiling in Early Breast Cancer-Patient Stratification Based on Molecular and Tumor Microenvironment...

Area of Science:

• Oncology
• Genomics
• Personalized Medicine

Background:

• Early-stage hormone receptor-positive, HER2-negative breast cancer (BC) treatment relies on clinical factors and biomarkers.
• Existing methods may not fully capture BC's molecular complexity.
• Tumor-infiltrating lymphocytes are emerging as important prognostic markers in specific BC subtypes.

Purpose of the Study:

• To evaluate the role of gene expression profiling (GEP) tests in refining treatment decisions for early-stage BC.
• To explore the potential of incorporating immune-related genes into GEPs for improved prediction of treatment response and prognosis.

Main Methods:

• Review of clinical trials and existing literature on GEP tests in BC.
• Analysis of clinicopathological factors and biomarker profiles (ER, PR, HER2).
• Consideration of prognostic and predictive value of tumor-infiltrating lymphocytes.

Main Results:

• GEP tests aid in predicting disease recurrence risk and chemotherapy benefit in luminal BC.
• GEPs complement clinicopathological parameters for personalized treatment strategies.
• Clinical trials validate the utility of GEP assays in various settings.

Conclusions:

• GEP tests are valuable tools for refining adjuvant systemic therapy decisions in early-stage BC.
• Future GEP refinement with immune-related genes holds promise for improved prediction of immunotherapy response and prognosis.
• Personalized treatment approaches are increasingly informed by molecular profiling.